RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection dynamics revealed by wastewater sequencing analysis and deconvolution
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.30.21266952
DO 10.1101/2021.11.30.21266952
A1 Schumann, Vic-Fabienne
A1 de Castro Cuadrat, Rafael Ricardo
A1 Wyler, Emanuel
A1 Wurmus, Ricardo
A1 Deter, Aylina
A1 Quedenau, Claudia
A1 Dohmen, Jan
A1 Faxel, Miriam
A1 Borodina, Tatiana
A1 Blume, Alexander
A1 Meixner, Martin
A1 Grau, José Horacio
A1 Liere, Karsten
A1 Hackenbeck, Thomas
A1 Zietzschmann, Frederik
A1 Gnirss, Regina
A1 Böckelmann, Uta
A1 Uyar, Bora
A1 Franke, Vedran
A1 Barke, Niclas
A1 Altmüller, Janine
A1 Rajewsky, Nikolaus
A1 Landthaler, Markus
A1 Akalin, Altuna
YR 2022
UL http://medrxiv.org/content/early/2022/05/03/2021.11.30.21266952.abstract
AB The use of RNA sequencing from wastewater samples is a valuable way for estimating infection dynamics and circulating lineages of SARS-CoV-2. This approach is independent from testing individuals and can therefore become the key tool to monitor this and potentially other viruses. However, it is equally important to develop easily accessible and scalable tools which can highlight critical changes in infection rates and dynamics over time across different locations given sequencing data from wastewater. Here, we provide an analysis of lineage dynamics in Berlin and New York City using wastewater sequencing and present PiGx SARS-CoV-2, a highly reproducible computational analysis pipeline with comprehensive reports. This end-to-end pipeline includes all steps from raw data to shareable reports, additional taxonomic analysis, deconvolution and geospatial time series analyses. Using simulated datasets (in silico generated and spiked-in samples) we could demonstrate the accuracy of our pipeline calculating proportions of Variants of Concern (VOC) from environmental as well as pre-mixed samples (spiked-in). By applying our pipeline on a dataset of wastewater samples from Berlin between February 2021 and January 2022, we could reconstruct the emergence of B.1.1.7(alpha) in February/March 2021 and the replacement dynamics from B.1.617.2 (delta) to BA.1 and BA.2 (omicron) during the winter of 2021/2022. Using data from very-short-reads generated in an industrial scale setting, we could see even higher accuracy in our deconvolution. Lastly, using a targeted sequencing dataset from New York City (receptor-binding-domain (RBD) only), we could reproduce the results recovering the proportions of the so-called cryptic lineages shown in the original study. Overall our study provides an in-depth analysis reconstructing virus lineage dynamics from wastewater, and that our tool can be used to identify new mutations and to detect any emerging new lineages with different amplification and sequencing methods. Our approach can support efforts to establish continuous monitoring and early-warning projects for detecting SARS-CoV-2 or any other pathogen.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data is available openly, and not human data at all.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available within the links provided in the manuscript https://github.com/BIMSBbioinfo/pigx_sarscov2_ww https://bimsbstatic.mdc-berlin.de/akalin/AAkalin_pathogenomics/sarscov2_ww_reports/220225_dataset_Berlin250/index.html https://bimsbstatic.mdc-berlin.de/akalin/AAkalin_pathogenomics/sarscov2_ww_reports/220310_dataset_Berlin35/index.html https://bimsbstatic.mdc-berlin.de/akalin/AAkalin_pathogenomics/sarscov2_ww_reports/220225_dataset_NYC_RBD/index.html https://bimsbstatic.mdc-berlin.de/akalin/AAkalin_pathogenomics/sarscov2_ww_reports/220309_ucsd_spikeIn/index.html https://bimsbstatic.mdc-berlin.de/akalin/AAkalin_pathogenomics/sarscov2_ww_reports/220310_insilico_simulation/insilico_simulation.html